Advertisement

Molecular Medicine

, Volume 20, Issue 1, pp 390–399 | Cite as

Lapatinib Antagonizes Multidrug Resistance-Associated Protein 1-Mediated Multidrug Resistance by Inhibiting Its Transport Function

  • Shao-lin Ma
  • Ya-peng Hu
  • Fang Wang
  • Zhen-cong Huang
  • Yi-fan Chen
  • Xiao-kun Wang
  • Li-wu Fu
Research Article

Abstract

Lapatinib, a tyrosine kinase inhibitor, is used in the treatment of advanced or metastatic breast cancer overexpressing human epidermal receptor 2 (HER2). Lapatinib can modulate the function of ATP-binding cassette (ABC) transporters (ABCB1 and ABCG2), which are the major mechanism responsible for multidrug resistance (MDR) in cancer. In this study, we investigated the effect of lapatinib on multidrug resistance-associated protein 1 (MRP1 (ABCC1)), MRP2 (ABCC2), MRP4 (ABCC4) and lung relative resistance protein (LRP) drug efflux pumps. We demonstrated that lapatinib could enhance the efficacy of conventional chemotherapeutic agents in MRP1-overexpressing cells in vitro and in vivo, but no effect in MRP2-, MPR4- and LRP-overexpressing cells. Furthermore, lapatinib significantly increased the accumulation of rhodamine 123 (Rho123) and doxorubicin (DOX) in MRP1-overexpressing cells. However, lapatinib did not alter the protein or mRNA expression levels of MRP1. Further studies showed that the level of phosphorylation of AKT and extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) were not altered at the indicated concentrations of lapatinib. In conclusion, lapatinib enhanced the efficacy of conventional chemotherapeutic agents in MRP1-overexpressing cells by inhibiting MRP1 transport function without altering the level of AKT or ERK1/2 phosphorylation. These findings will encourage the clinical research of lapatinib combined with conventional chemotherapeutic drugs in MRP1-overexpressing cancer patients.

Notes

Acknowledgments

We thank Zhe-Sheng Chen (St. John’s University, Queens, NY, USA) for the NIH3T3 and NIH3T3/MRP4-2 cell lines and professor Kenneth To (The Chinese University of Hong Kong) for comments. The work was supported by grants from National Science and Technology Major Projects of the National Basic Research Program (973 Program) of China (2012CB967004 for L-w Fu), 863 Program of China (2012AA02A303 for L-w Fu), National Natural Sciences Foundation of China (81061160507 and 81072669 for L-w Fu), Nature Science Foundation (excellent PhD dissertation foundation) of the Guangdong province (8400-3226201) and Natural Science Foundation of Guangzhou (12C32061587).

References

  1. 1.
    Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. (2006) Targeting multidrug resistance in cancer. Nat. Rev. Drug. Discov. 5:219–34.CrossRefPubMedGoogle Scholar
  2. 2.
    Leonard GD, Fojo T, Bates SE. (2003) The role of ABC transporters in clinical practice. Oncologist. 8:411–24.CrossRefPubMedGoogle Scholar
  3. 3.
    Ozben T. (2006) Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580:2903–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Perez-Tomas R. (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 13:1859–76.CrossRefPubMedGoogle Scholar
  5. 5.
    Chen ZS, Tiwari AK. (2011) Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. 278:3226–45.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fukuda Y, Schuetz JD. (2012) ABC transporters and their role in nucleoside and nucleotide drug resistance. Biochem. Pharmacol. 83:1073–83.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Borst P, Evers R, Kool M, Wijnholds J. (2000) A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:1295–302.CrossRefPubMedGoogle Scholar
  8. 8.
    Cole SP, Deeley RG. (2006) Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol. Sci. 27:438–46.CrossRefPubMedGoogle Scholar
  9. 9.
    Rea PA. (2007) Plant ATP-binding cassette transporters. Annu. Rev. Plant Biol. 58:347–75.CrossRefPubMedGoogle Scholar
  10. 10.
    Cole SP, et al. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1650–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Kubota T, et al. (2001) Resistant mechanisms of anthracyclines: pirarubicin might partly break through the P-glycoprotein-mediated drug-resistance of human breast cancer tissues. Breast Cancer. 8:333–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Nooter K, et al. (1995) Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin. Cancer Res. 1:1301–10.PubMedGoogle Scholar
  13. 13.
    Flens MJ, et al. (1996) Tissue distribution of the multidrug resistance protein. Am. J. Pathol. 148:1237–47.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Leslie EM, Deeley RG, Cole SP. (2001) Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology. 167:3–23.CrossRefPubMedGoogle Scholar
  15. 15.
    Aller SG, et al. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 323:1718–22.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Borst P, Elferink RO. (2002) Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71:537–92.CrossRefPubMedGoogle Scholar
  17. 17.
    Deeley RG, Westlake C, Cole SP. (2006) Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 86:849–99.CrossRefPubMedGoogle Scholar
  18. 18.
    Homolya L, Varadi A, Sarkadi B. (2003) Multidrug resistance-associated proteins: export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors. 17:103–14.CrossRefPubMedGoogle Scholar
  19. 19.
    Narasaki F, et al. (1997) Human canalicular multispecific organic anion transporter (cMOAT) is expressed in human lung, gastric, and colorectal cancer cells. Biochem. Biophys. Res. Commun. 240:606–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Koike K, et al. (1997) A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res. 57:5475–9.PubMedGoogle Scholar
  21. 21.
    Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH. (1997) Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. Int. J. Cancer. 72:1021–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Dalton WS, Scheper RJ. (1999) Lung resistance-related protein: determining its role in multidrug resistance. J. Natl. Cancer Inst. 91:1604–5.CrossRefPubMedGoogle Scholar
  23. 23.
    Izquierdo MA, et al. (1995) Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J. Natl. Cancer Inst. 87:1230–7.CrossRefPubMedGoogle Scholar
  24. 24.
    Volm M, Stammler G, Zintl F, Koomagi R, Sauerbrey A. (1997) Expression of lung resistance-related protein (LRP) in initial and relapsed childhood acute lymphoblastic leukemia. Anticancer Drugs. 8:662–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Jagiello-Gruszfeld A, et al. (2010) A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. Oncology. 79:129–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Dai CL, et al. (2008) Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 68:7905–14.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Kuang YH, et al. (2010) Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem. Pharmacol. 79:154–61.CrossRefPubMedGoogle Scholar
  28. 28.
    Sumizawa T, et al. (1994) Non-P-glycoprotein-mediated multidrug-resistant human KB cells selected in medium containing adriamycin, cepharanthine, and mezerein. Somat. Cell Mol. Genet. 20:423–35.CrossRefPubMedGoogle Scholar
  29. 29.
    Cui Y, et al. (1999) Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol. 55:929–37.PubMedGoogle Scholar
  30. 30.
    Lee K, Klein-Szanto AJ, Kruh GD. (2000) Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. 92:1934–40.CrossRefPubMedGoogle Scholar
  31. 31.
    Chen LM, et al. (2004) Screening novel, potent multidrug-resistant modulators from imidazole derivatives. Oncol. Res. 14:355–62.CrossRefPubMedGoogle Scholar
  32. 32.
    Shi Z, et al. (2006) Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol. Ther. 5:39–47.CrossRefPubMedGoogle Scholar
  33. 33.
    Mi YJ, et al. (2010) Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters. Cancer Res. 70:7981–91.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Chen LM, et al. (2004) Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. J. Pharm. Pharmacol. 56:1061–6.CrossRefPubMedGoogle Scholar
  35. 35.
    Fu L, et al. (2004) Characterization of tetrandrine, a potent inhibitor of P-glycoprotein-mediated multidrug resistance. Cancer Chemother. Pharmacol. 53:349–56.CrossRefPubMedGoogle Scholar
  36. 36.
    Zheng LS, et al. (2009) Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One. 4:e5172.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Livak KJ, Schmittgen TD. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402–8.CrossRefGoogle Scholar
  38. 38.
    Gagnon V, Van Themsche C, Turner S, Leblanc V, Asselin E. (2008) Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis. 13:259–71.CrossRefPubMedGoogle Scholar
  39. 39.
    Oh SY, et al. (2006) ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance. Exp. Cell Res. 312:1651–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Goldstein LJ, et al. (1989) Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81:116–24.CrossRefPubMedGoogle Scholar
  41. 41.
    Diestra JE, et al. (2002) Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J. Pathol. 198:213–9.CrossRefPubMedGoogle Scholar
  42. 42.
    Sarkadi B, Homolya L, Szakacs G, Varadi A. (2006) Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol. Rev. 86:1179–236.CrossRefPubMedGoogle Scholar
  43. 43.
    Hanks SK, Quinn AM, Hunter T. (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 241:42–52.CrossRefGoogle Scholar
  44. 44.
    Radha V, Nambirajan S, Swarup G. (1996) Association of Lyn tyrosine kinase with the nuclear matrix and cell-cycle-dependent changes in matrix-associated tyrosine kinase activity. Eur. J. Biochem. 236:352–9.CrossRefPubMedGoogle Scholar
  45. 45.
    Ruetten H, Thiemermann C. (1997) Effects of tyrphostins and genistein on the circulatory failure and organ dysfunction caused by endotoxin in the rat: a possible role for protein tyrosine kinase. Br. J. Pharmacol. 122:59–70.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Hegedus T, et al. (2002) Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta. 1587:318–25.CrossRefPubMedGoogle Scholar
  47. 47.
    Erlichman C, et al. (2001) The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance proteinmediated drug efflux. Cancer Res. 61:739–48.PubMedGoogle Scholar
  48. 48.
    Kitazaki T, et al. (2005) Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer. 49:337–43.CrossRefPubMedGoogle Scholar
  49. 49.
    Shi Z, et al. (2007) Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 67:11012–20.CrossRefPubMedGoogle Scholar
  50. 50.
    Wang F, et al. (2014) Nilotinib enhances the efficacy of conventional chemotherapeutic drugs in CD34(+)CD38(−) stem cells and ABC transporter overexpressing leukemia cells. Molecules. 19:3356–75.CrossRefPubMedGoogle Scholar
  51. 51.
    Sun YL, et al. (2014) Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncol Rep. 31:1605–12.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Castellino S, et al. (2012) Human metabolism of lapatinib, a dual kinase inhibitor: implications for hepatotoxicity. Drug Metab. Dispos. 40:139–50.CrossRefPubMedGoogle Scholar
  53. 53.
    Takakusa H, et al. (2011) Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib. Drug Metab. Dispos. 39:1022–30.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Nettleton DO, Einolf HJ. (2011) Assessment of cytochrome p450 enzyme inhibition and inactivation in drug discovery and development. Curr. Top. Med. Chem. 11:382–403.CrossRefPubMedGoogle Scholar
  55. 55.
    Normanno N, et al. (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 366:2–16.CrossRefPubMedGoogle Scholar
  56. 56.
    Grant S, Qiao L, Dent P. (2002) Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci. 7:d376–89.CrossRefPubMedGoogle Scholar
  57. 57.
    Knuefermann C, et al. (2003) HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene. 22:3205–12.CrossRefPubMedGoogle Scholar
  58. 58.
    Li QQ, et al. (2007) Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci. 98:1064–9.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Shao-lin Ma
    • 1
  • Ya-peng Hu
    • 1
  • Fang Wang
    • 1
  • Zhen-cong Huang
    • 1
  • Yi-fan Chen
    • 1
  • Xiao-kun Wang
    • 1
  • Li-wu Fu
    • 1
  1. 1.Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South ChinaCancer Center of Sun Yat-Sen UniversityGuangzhouChina

Personalised recommendations